Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Other 1

Conditions

Opioid-Induced Constipation 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × naldemedine × Clear all
NCT03720613 2025-02-12

Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation

BioDelivery Sciences International

Recruiting
34,532 enrolled
Other

Opioid-Induced Constipation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡